Zhejiang Jiuzhou Pharmaceutical (SHA:603456) subsidiary Zhejiang Ruibo passed an on-site Current Good Manufacturing Practice inspection conducted by the US Food and Drug Administration.

The inspection covered quality systems, materials, production, packaging, labeling, equipment, and laboratory controls, according to a Thursday filing with the Shanghai bourse.

The inspection site was the active pharmaceutical ingredient base at 18 Nanyang 3rd Road, Linhai Park in China's Zhejiang province.

Shares of the drugmaker closed 1% higher Thursday.